Icad Inc (ICAD)

Stock is still trading at a 3.8% discount to RDNT based upon .0677/ share deal. Easy abritage as this deal will surely close as break up fee is too large for ICAD to terminate.
Those who sold at under $3.30 when deal was announced are regretting their decision, but to each their own.
RDNT also good buy going forward imo.

do not buy georgie georgie

ICAD...$3.30...🥳...Just Noticed this...No Position...https://www.globenewswire.com/news-release/2025/04/15/3062106/10985/en/RadNet-Inc-to-Acquire-iCAD-Inc-to-Accelerate-AI-Powered-Early-Detection-and-Diagnosis-of-Breast-Cancer.html

Picked up some at $2.50

30k share sell block drove the price under 3 and now volume is starting to pick up. Still churning in the 2.90's.

See how the stock reacts around 3.00 ....should be some support.   Investor conference last week. Funds are likely fishing for discounted shares.

Honestly I think there may be a flash drop to $2.70 area but anything between 2.70 and 3 is a good pickup if you have a one year horizon.

Price is going to test that 3.76 resistance area again. Figuring a double top but won't know until we actually get there and see the trading action.

Top in

ICAD the bio beast breaks it’s chains here

Slams right into $3.76 resistance and pulls back a bit.   Time for the stock to consolidate its gains before the next move higher.

ICAD 3.47 here we go

ICAD 3.38 TRIGGER

ICAD 3.47 MAGNET

Not much resistance until 3.76 if 3.35 holds.

ICAD THERES THE BREAK

ICAD BREAKS THAT 3.35 VERY SOON

Acceleration growth of deals is the key here. Would like to know if there is any churn on these deals or if once customers signs up they love the product/service so much they keep adding to their deals.

ICAD THIS BEAST IS READY TO BEAST TOA NEW HIGH OF THE DAY

Only 26.5 million shares outstanding. 

ICAD READY TO RUMBLE

Quick rip to 3, then a quicker rip back to $2.70. Do MM's need shares or does it need a breather in this area?   I'm betting the former but who knows. It's certainly allowing folks to load right here if they want to.

Preannounced $5.1-5.3 million revenues versus $4.2 million in the last quarter.  Love sequential growth, not just YOY growth.  

They company has the momentum right now!

ICAD BEASTING BIO READY TO BEAST

It traded even higher than 20 back in the day, Stock chart history has a way of repeating but please give a little bit more time for me to build my position 😉

No better story than combining AI with breast cancer prevention .

Years ago this stock traded at 20 and it should be able to do that again within 24 months as long as sales team keeps adding new customers.

I've been building a position here mid Dec from about $1.75 on up.

Line I said previously, I believe this will be a 2025 story. subscription has smoothed out revenues but sales team is scoring about 50-60 new clients per quarter. Hopefully we see an acceleration this year due to all the AI driven news.

Making a move near $2.50

$iCAD Let's Go!

https://www.globenewswire.com/news-release/2024/11/12/2979073/0/en/iCAD-s-ProFound-Detection-Version-4-0-Gains-FDA-Clearance.html

keep watching next two Q ICAD to $15
outlook breast cancer analysis and breast health at finger tip.

Don't miss
buying now means buying at 75% discount from EOY

keep eye on this one. $5 -$10 by 4thQ 24 or 1stQ25
product & service rev and profit margin likely +100% by 4thQ

no - wow not expired
they were slow to catch up and now ready and rapidly getting accepted in the society

wont be surprised if it start dancing soon. 2x 5x 10x even 20x

Book Value Per Share (mrq) 1.23
implied Shares Outstanding 26.54M
Revenue (ttm) 17.94M
Total Cash (mrq) 19.68M
debt 0, SP 1.3
just 40 year old company.
looks interesting but likely expired

Good to be a bumpy ride with this company. The Q&A from last quarter indicated an unevenness in future quarterly revenues which makes me think the next reported quarter won’t be as good as folks think. Guessing the Q ending 9/30 will be much better though.

ICAD under $2

What’s with this company?

BOD voted their executives some very rich pay packages for FY24.

Likely to make up for no bonuses awarded in FY24.

And those looking for an up-and-coming growth name with tremendous potential in the AI space should consider iCAD (NASDAQ: ICAD). The firm uses AI to detect breast cancer more proficiently than mammographies, and it has formed alliances with GE Healthcare (NASDAQ:GEHC), Alphabet (NASDAQ:GOOG,GOOGL), and two of America’s largest owners of clinics that specialize in mammographies.

In my view, iCAD’s current market capitalization of $38 million far undervalues the firm.

On the date of publication, Larry Ramer held long positions in SMCI and ICAD. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.

5 AI Stocks to Buy Before They Skyrocket

?

3 AI-Driven Stocks That Will Be the Next Trillion-Dollar Companies

America’s #1 Top Trader, Eric Fry, just released his latest AI recommendations with trillion-dollar market cap valuations. Learn their names & full backstories in his new report while they’re still considered a bargain. Enter your email below to get your free copy of “3 AI-Driven Stocks That Will Be the Next Trillion-Dollar Companies” and a complimentary subscription to Eric Fry’s Smart Money e-letter. Get your FREE report now!

Submit

SPONSORED HEADLINES

?

5 Artificial Intelligence Stocks to Buy Before They Skyrocket

?

The Top 7 Stocks for 2024

?

ChatGPT IPO Could Shock the World, Make This Move Before the Announcement

?

“America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out

MORE FROM INVESTORPLACE

?

MARKET ANALYSIS

Why Today’s Inflation-Driven Flush Comes at the Perfect Time

17h ago · By Luke Lango, InvestorPlace Senior Investment Analyst

?

MARKET ANALYSIS

The Quest for Value: Intel vs. India Stocks

18h ago · By Eric Fry, Editor, Fry's Investment Report

?

TODAY'S MARKET

Mizuho Just Raised Its Price Target on Nvidia (NVDA) Stock

18h ago · By Chris MacDonald, InvestorPlace Contributor

 

 

About InvestorPlace

 

Products

 

Contact Us

 

Help

 

Careers

 

Advertise With Us

 

Disclosures & Disclaimers

 

Privacy Policy

 

Terms of Use

 

Ad Choices

 

Do Not Sell My Personal Information

 

Cookie Preferences

 

DMCA Policy

Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Copyright © 2024 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201.

Looking good

Partnerships keep coming,will pay off soon

During the third quarter, the company generated net proceeds of approximately $1.8 million from the issuance of 958,248 shares of common stock in the aftermarket ATM offerings at a weighted average price of $2.26 per share.

Only one analyst on the call. Now a standalone product line. They are hiring a bunch of new sales reps to try and get back the maintenance business that wasn’t renewed by prior customers. They said they won’t need to raise additional cash but revenue gains are going to be slow over the next year with this really being a 2025 story.

Retracement to lows from summer and getting a bounce now. Good time to start a position imo.

With the sale of Xsoft , expect the company to lose about $1.7 quarterly sales going forward (about $6.8 million annually). However it was never a money maker for them . Someone else will do a better job with the technology.

The Company currently expects to report revenue for the three months ended September 30, 2023 of between $5.4 million and $5.6 million. In addition, the Company expects total operating expenses for such period of between $5.5 million and $5.7 million. These expected results are not final and it is possible they will change upon filing of Form 10-Q on or before November 14, 2023.

Until some of the insiders step up to the plate and purchase their stock (not counting option grants) this is a no go for me right now. Obviously $1.70 is too expensive for even them at this point.

Craig-Hallum Capital is raising money thru the share offering any time the share price rises above 2.

Unfortunately, at some point, IMO they will lower that price ten cents at a time.

Yeah I must have missed it

Was this news even release by icad?

https://www.prnewswire.com/news-releases/simonmed-imaging-implements-3rd-generation-icad-breast-ai-3-0--301867503.html

Artificial Intelligence Mammograms - SimonMed Website https://www.simonmed.com/artificial-intelligence-mammograms/